Research programme: combination therapies - TRINITY Laboratories

Drug Profile

Research programme: combination therapies - TRINITY Laboratories

Alternative Names: Dextromethorphan/gabapentin/tramadol; Dextromethorphan/sildenafil/tramadol; TLI 0651; TLI 1026

Latest Information Update: 23 Jan 2016

Price : $50

At a glance

  • Originator Trinity Laboratories
  • Class Small molecules
  • Mechanism of Action NMDA receptor antagonists; Opioid mu receptor agonists; Serotonin uptake inhibitors; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Dysmenorrhoea; Fibromyalgia; Neuropathic pain

Most Recent Events

  • 22 Jan 2016 TRINITY Laboratories has patent protection for TLI 1026 and treatment of premature ejaculation in USA
  • 22 Jan 2016 TRINITY laboratories plans a phase I trial for Dysmenorrhoea in USA (TRINITY website, January 2016)
  • 21 Jan 2016 Preclinical trials in Dysmenorrhoea in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top